Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioject extends supply agreement with Ferring Pharmaceuticals
The new agreement extends the most recent agreement for an additional three years with two consecutive one year renewal options. The Bioject drug vial adapter is a needle-free
The new agreement extends the most recent agreement for an additional three years with two consecutive one year renewal options. The Bioject drug vial adapter is a needle-free
Sodium-dependent glucose co-transporter type 2 (SGLT2) is the major transporter responsible for glucose re-absorption in the kidney. Decreasing SGLT2 levels promote glucose excretion in the urine and reduce
Earlier, the company submitted its response to the FDA complete response letter for paliperidone palmitate, received in August 2008. Paliperidone palmitate is an investigational once-monthly atypical antipsychotic injection
The investment, which originated from Paul Manning, a director of the National Neurovision Research Institute (NNRI), is supporting the continuing development of StarGen. StarGen is Oxford BioMedica’s novel
The award funds continued development of PL 4500, a molecular complex of indomethacin and phosphatidylcholine that is being developed as a gastrointestinal (GI) safer anti-inflammatory and analgesic in
Under a collaboration agreement between the University of California, San Diego (UCSD) and Raptor, UCSD is conducting the Phase IIa clinical trial at UCSD’s General Clinical Research Center.
Further, AspenBio Pharma said it promoted Mark Colgin to a new position of chief scientific officer. “We are very grateful for Rich’s invaluable contribution over the last few
Revenues for the fourth quarter of 2008 were $10.1 million, up from $7.8 million in the fourth quarter of 2007. For the full year 2008, revenues were $35.2
Reported sales of $510 million in the fourth quarter ended December, 2008 declined by 4% compared to 2007. Excluding the impact of currency, sales in the fourth quarter
The new agreement addresses the five existing technologies and two applications in development of the Artelon spacer portfolio designed to treat arthritis within small bone and joints. Small